Parexel has confirmed that Panthera Biopartners has become the first UK public or commercial clinical trial organisation to become part of the Parexel Site Alliance Vaccine Network. Parexel’s Site Alliance Vaccine Network is a global network of high performing clinical trial sites which fosters long-term collaborative relationships with select research organizations across the globe to …
Since announcing that it reopened its oncology clinical trials division earlier this year, Panthera Biopartners has been selected by two of the world’s largest pharma companies to run oncology trials at sites across the UK. Panthera previously had to close its Oncology division as the sites were located inside the four Rutherford Specialist Cancer clinics, …
Panthera’s SMO model delivers market-leading patient recruitment for vaccine trials In the post-COVID-19 period, the UK has emerged as a world leader in vaccine trials, but data from two case studies shows that Panthera is not only outperforming global sites, but also competitor sites across the UK. In a recent COVID-19 booster healthy volunteer vaccine trial, Panthera’s …
The UK’s largest Site Management Organisation (SMO), Panthera Biopartners, has opened the first dedicated clinical research site in York. The site, which has been operating since May, was officially opened by the Lord Mayor of York, Councillor Margaret Wells, at an opening ceremony on 25th July 2024. The clinic is located in the Acomb Garth …
Click here to read more: https://lnkd.in/erHjBc6k Includes:* Panthera remains top recruiter of patients in the UK* Panthera delivers outstanding patient recruitment for cardiovascular trials* Panthera launches new clinical research clinic in York* International Clinical Trials interview – Private vs public vaccine studies, how SMOs can secure the future of UK clinical trials* Martyn Jellett appointed as …
Independent clinical trial SMO (Site Management Organisation) Panthera Biopartners has appointed Martyn Jellett as Associate Director Business Development to support its expanding commercial team as the company continues to prosper and expand. Martyn has over 25 years experience in professional sales and business development and has extensive knowledge of the pharmaceutical and medical industry. Panthera, …
International Clinical Trials (ICT): Panthera interview – Private vs public vaccine studies, how SMOs can secure the future of UK clinical trials Panthera’s Ian Smith and Chris Dodd recently spoke to ICT about the differences in private versus public clinical trials, how speed is key in preclinical processes and how the UK can improve its …
Lord James O’Shaughnessy, former Health Minister, has been appointed by the UK government to conduct an independent review of the country’s commercial clinical trials landscape. The review will advise on how to resolve key challenges in conducting commercial clinical trials and ensure that the UK remains a global leader in the field. Lord O’Shaughnessy’s advice is expected to be published this spring.
Panthera Biopartners raises £10 million to accelerate its dedicated clinical trial site expansion across the UK and Western Europe Panthera Biosciences (Panthera) has secured £10 million of investment from BGF and Gresham House Ventures, the latter investing on behalf of the Baronsmead VCTs. This investment will allow Panthera to further grow its network of dedicated …
Valneva have released results from their phase 3 vaccine study (VLA2001). Stating that the trial has successfully met both co-primary end points. This trial compared the efficacy and effectiveness of the Valneva Covid-19 vaccine against the AstraZeneca vaccine. A total of 4012 people, aged 18 years and above were recruited to this clinical trial, across …
